Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

TERMINATED

Status

1166

Enrollment

INDUSTRY

Sponsor class

Stopped In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs

Conditions

Hypercholesterolemia
Mixed Dyslipidemia

Interventions

DRUG: Niacin (+) laropiprant

Sponsor

Merck Sharp & Dohme LLC